INTEGRATED DRUG CREATION
Dead / Abandoned — Abandoned — failure to respond (as of 26 Mar 2026)
What this means for you
This application is over — abandoned 11 Mar 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 99137348
- Mark type
- Stylized text
- Filed
- 15 Apr 2025
- Abandoned
- 11 Mar 2026
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 040 — Treatment of materials: Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
- Class 042 — Scientific and technological services: Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
Owner
- Absci Corporation, Vancouver, WA, US
Prosecution history
- 26 Mar 2026 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 26 Mar 2026 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 09 Dec 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 09 Dec 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 10 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Sept 2025 — NON-FINAL ACTION E-MAILED
- 10 Sept 2025 — NON-FINAL ACTION WRITTEN
- 10 Sept 2025 — ASSIGNED TO EXAMINER
- 15 Apr 2025 — APPLICATION FILING RECEIPT MAILED
- 15 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 15 Apr 2025 — NEW APPLICATION ENTERED